What is Nabsys?
Headquartered in Providence, Rhode Island, Nabsys is a pioneering biotechnology firm dedicated to advancing the understanding of human disease. By enabling routine, accurate, and cost-effective analysis of genomic structural variation, the company provides essential tools that increase diagnostic yield and improve patient outcomes. Nabsys operates at the intersection of advanced engineering and molecular biology, employing a multidisciplinary team of scientists and professionals focused on the commercialization of high-throughput genomic platforms. Their market position is defined by a commitment to precision medicine, where the ability to detect complex structural changes in the genome is becoming increasingly vital for therapeutic development and personalized healthcare strategies.
How much funding has Nabsys raised?
Nabsys has raised a total of $117.5M across 13 funding rounds:
Series C
$10M
Debt
$4.7M
Grant
$244K
Private Equity
$25.5M
Private Equity
$6M
Other Financing Round
$21M
Debt
$150K
Private Equity
$38M
Series C (2011): $10M, investors not publicly disclosed
Debt (2012): $4.7M, investors not publicly disclosed
Grant (2012): $244K supported by Internal Revenue Service
Private Equity (2014): $25.5M featuring Bay City Capital and Rose Ventures, Inc
Private Equity (2016): $6M backed by Jilin Zixin Pharmaceutical Industrial Co., Ltd
Other Financing Round (2019): $21M with participation from Hitachi High-Technologies Corporation
Debt (2020): $150K led by PPP
Private Equity (2022): $38M supported by Hitachi High-Tech Corporation
Key Investors in Nabsys
Bay City Capital
A venture capital firm founded in 1997 that specializes in investing in life sciences, managing significant capital commitments to support innovative therapeutic advancements.
Slater Technology Fund
An evergreen not-for-profit seed fund dedicated to supporting new venture development in Rhode Island, serving as a primary catalyst for regional technology growth.
Point Judith Capital
An early-stage venture capital firm based in Boston, Massachusetts, focused on building long-term relationships with entrepreneurs and supporting high-growth technology ventures.
What's next for Nabsys?
With the recent influx of capital, Nabsys is well-positioned to accelerate its strategic roadmap, focusing on the broader adoption of its genomic analysis platforms. The company is expected to leverage this financial backing to enhance its R&D capabilities, expand its commercial footprint, and deepen its integration within the global life sciences ecosystem. As the demand for high-resolution genomic data continues to rise, Nabsys is poised to capitalize on its technological advantages, potentially driving new standards in diagnostic accuracy. Future growth will likely center on scaling manufacturing processes and fostering collaborative partnerships with clinical research organizations to solidify its role as a cornerstone of modern genomic infrastructure.
See full Nabsys company page
